Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil S Dhawan

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature|August 25, 2016
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signallingNeil S Dhawan, Alex P Scopton, Arvin C Dar
Bioorganic & Medicinal Chemistry|September 16, 2015
Reengineered tricyclic anti-cancer agentsDavid B Kastrinsky, Jaya Sangodkar, Nilesh Zaware, et al.
Bioorganic & Medicinal Chemistry|March 15, 2017
Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]David B Kastrinsky, Jaya Sangodkar, Nilesh Zaware, et al.
Neuro-Oncology|July 30, 2011
Gene-protein correlation in single cellsJaclyn J Renfrow, Adrienne C Scheck, Neil S Dhawan, et al.
JCI Insight|March 5, 2019
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinomaRita Tohmé, Sudeh Izadmehr, Sai Gandhe, et al.
The Journal of Clinical Investigation|June 2, 2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment responseJaya Sangodkar, Neil S Dhawan, Heather Melville, et al.
The Journal of Clinical Investigation|May 16, 2017
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growthJaya Sangodkar, Abbey Perl, Rita Tohme, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature|August 25, 2016
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signallingNeil S Dhawan, Alex P Scopton, Arvin C Dar
Bioorganic & Medicinal Chemistry|September 16, 2015
Reengineered tricyclic anti-cancer agentsDavid B Kastrinsky, Jaya Sangodkar, Nilesh Zaware, et al.
Bioorganic & Medicinal Chemistry|March 15, 2017
Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]David B Kastrinsky, Jaya Sangodkar, Nilesh Zaware, et al.
Neuro-Oncology|July 30, 2011
Gene-protein correlation in single cellsJaclyn J Renfrow, Adrienne C Scheck, Neil S Dhawan, et al.
JCI Insight|March 5, 2019
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinomaRita Tohmé, Sudeh Izadmehr, Sai Gandhe, et al.
The Journal of Clinical Investigation|June 2, 2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment responseJaya Sangodkar, Neil S Dhawan, Heather Melville, et al.
The Journal of Clinical Investigation|May 16, 2017
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growthJaya Sangodkar, Abbey Perl, Rita Tohme, et al.
Pageof 1